Why the study?
Cellular senescence contributes to aging and cardiovascular pathologies, but knowledge gaps remain regarding its systemic effects and the therapeutic potential of targeting senescence.
Does targeting cellular senescence with senolytics improve outcomes across age-related cardiovascular diseases such as atherosclerosis, myocardial infarction, heart failure, hypertension, and arrhythmias?
Does targeting cellular senescence with senolytics improve outcomes across age-related cardiovascular diseases such as atherosclerosis, myocardial infarction, heart failure, hypertension, and arrhythmias?
This narrative review synthesizes preclinical and mechanistic evidence demonstrating that cellular senescence drives diverse age-related cardiovascular pathologies and highlights both the therapeutic potential and current translational knowledge gaps of senolytic drugs.
Answers are grounded in this paper and cite their sources.
Senescence-targeted interventions merit exploration in age-related CVD; leaves open clinical translation from current preclinical and observational links.
The prevalence of cardiovascular diseases markedly rises with age. Cellular senescence, a hallmark of aging, is characterized by irreversible cell cycle arrest and the manifestation of a senescence-associated secretory phenotype, which has emerged as a significant contributor to aging, mortality, and a spectrum of chronic ailments. An increasing body of preclinical and clinical research has established connections between senescence, senescence-associated secretory phenotype, and age-related cardiac and vascular pathologies. This review comprehensively outlines studies delving into the detrimental impact of senescence on various cardiovascular diseases, encompassing systemic atherosclerosis (including coronary artery disease, stroke, and peripheral arterial disease), as well as conditions such as hypertension, congestive heart failure, arrhythmias, and valvular heart diseases. In addition, we have preclinical studies demonstrating the beneficial effects of senolytics-a class of drugs designed to eliminate senescent cells selectively across diverse cardiovascular disease scenarios. Finally, we address knowledge gaps on the influence of senescence on cardiovascular systems and discuss the future trajectory of strategies targeting senescence for cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: